DR. ERIC HUANG

Dr. Eric Huang joined Delos Capital as a Senior Advisor in 2020 and served as an Operating Partner before transitioning to a full-time role as a Partner in April 2024. Prior to this, he held the position of General Manager and Chief Scientific Officer (CSO) at Moderna Genomics, where he led a collaborative effort to establish and grow a research organization focused on discovering and developing next-generation genomic medicines. Eric’s vision and leadership were instrumental in integrating the company’s advanced mRNA foundation with cutting-edge gene editing technologies and innovative genetics research, driving the organization’s success.

Before his role at Moderna Genomics, Eric was the founding CSO of the Autoimmune Therapeutic Area at Moderna, where he had the privilege of working with a talented team to set a strategic direction for the portfolio, create a product pipeline and a robust discovery engine, and lead the preclinical development to the group’s first Investigational New Drug (IND) application. As the CSO of Moderna’s New Venture Labs (NVL), an industry-leading internal incubator, Eric guided a select group of scientists in exploring novel applications of mRNA technology across various fields, including immunology, neurology, tissue repair & regeneration, and cancer. This role marked his first leadership position in R&D, and he personally conceived the groundbreaking idea of using the mRNA platform for vaccines. His mechanism-based approach, multidisciplinary expertise, and ability to synthesize knowledge from diverse fields were key to demonstrating the platform’s power, which later led to the development of the COVID-19 vaccine. Eric was recognized with the prestigious Warren Alpert Foundation Prize for his pioneering work on the mRNA vaccine platform. Additionally, NVL successfully launched Moderna’s personalized cancer vaccine and its Autoimmune Therapeutic Area division.

His earlier career includes successful roles in business and corporate development at several venture-backed biotechnology companies, including Seaside Therapeutics, Stromedix, and Domantis. In these positions, he consistently applied his diverse skill set and strategic thinking to learn from and contribute to the growth and innovation of these organizations.

Eric holds a Ph.D. in Molecular and Medical Parasitology from New York University and an MBA from Boston University. He also earned a B.S. from Emory University and is a proud Rocker with an A.A. from Bard College at Simon’s Rock.​​